Sunday, November 15, 2026

Peer-Reviewed Clinical Evidence Platform

The research that matters, without the jargon.

Peer-reviewed breakthroughs in plain English alongside verified outcomes, evidence grades, and clinical study details for everyone from everyday readers to medical students.

ClearMed Editorial Digest500 briefings across 12 specialties121 Phase III & clinical practice

Indexed from PubMed, NEJM, The Lancet, JAMA, Nature MedicineSaved Library

Health Hubs:

Stage: Evidence:

Showing 20 briefings matching “lipid”

Reset all filters

Filtered Archive

Matching Peer-Reviewed Briefings

Peer-Reviewed Clinical Digests · Verified Scientific Media

IMMUNOLOGY · PRECLINICAL

Compartment-specific PPARδ activity controls the outcome of cancer-immune cell competition and immunotherapy efficacy

These findings identify compartment-specific PPARδ activity as a targetable driver of immune cell fitness that can be harnessed to improve outcomes in immunotherapy-resistant tumors. Therapeutically, PPARδ-activated CD8 + T cells sensitize immunotherapy-resistant microsatellite stable metastatic colorectal cancer to checkpoint blockade in mice, and pharmacological or genetic PPARδ activation enhances human chimeric antigen receptor T cell function.

2/5 Preclinical

Evidence Meter · 2/5

Animal & Preclinical Data

Demonstrated in living animal models before large-scale human safety and dosing trials begin.

1 min readNature ImmunologyNov 14, 2026

CARDIOLOGY · PHASE III

Coronary Artery Calcium Scoring: A New Paradigm for Statin Allocation and Adherence?

Using coronary artery calcium (CAC) scoring to guide statin initiation reduces statin prescriptions without compromising major cardiovascular event prevention, while significantly improving medication adherence. Current guidelines from bodies like the ACC/AHA primarily utilize traditional risk assessment tools, such as the Pooled Cohort Equations, to identify individuals at intermediate to high risk for atherosclerotic cardiovascular disease (ASCVD) who would benefit from statin therapy.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readScienceDailyNov 12, 2026

CARDIOLOGY · REAL-WORLD COHORT

Cardiovascular Health Promotion for US Veterans: Current State, Gaps, and Strategies: A Scientific Statement From the American Heart Association

Addressing these challenges at the Veterans Affairs will require continuing to expand care access, enhancing digital data integration, tailoring interventions to high-risk subgroups, and strengthening implementation strategies to improve uptake and engagement across Veterans Affairs services. Weight Management Program for Veterans, Whole Health, telehealth-based interventions, and integrated mental health and substance use disorder services.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readCirculationNov 11, 2026

CARDIOLOGY · REAL-WORLD COHORT

AI-Identified Reasons for Nonescalation of Lipid-Lowering Therapy for Secondary Prevention

Results of this study show that after using a state-of-the art LLM, nearly 9 in 10 ASCVD encounters with above-goal LDL-C level did not have patient LLT escalated, most often because of adverse effects, patient preference, preference for lifestyle changes, therapeutic inertia (eg, repeat laboratory tests), and near-goal LDL-C level. These findings highlight an avenue for personalizing system-level digital health interventions to help discover and minimize guideline-discordant care gaps in secondary prevention of ASCVD.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readJAMA CardiologyNov 7, 2026

CARDIOLOGY · RANDOMIZED CLINICAL TRIAL

Statin-Ezetimibe Combination Therapy versus Statin Monotherapy in Atherosclerotic Cardiovascular Disease: A Prespecified Secondary Analysis of the Randomized Ez-PAVE Trial

Within a target-directed LDL-C-lowering strategy, cardiovascular efficacy (real-world effectiveness in the trial) and safety did not differ significantly, whether initiated as statin-ezetimibe combination therapy or as statin monotherapy, but combination therapy facilitated achievement of a lower LDL-C target. In a target-directed low-density lipoprotein cholesterol (LDL-C)-lowering strategy, the impact of the initial treatment regimen has not been investigated in patients with atherosclerotic cardiovascular disease.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readCirculationNov 7, 2026

ENDOCRINOLOGY · CLINICAL PRACTICE

Beyond singular effectors: The futile creatine cycle from molecular mechanism to integrated adipocyte thermogenesis

The FCC thus offers a reference point for connecting the biochemical mechanisms of other thermogenic cycles to their physiological contributions. They establish physiological relevance beyond what maximal respiratory rates in reductionist systems alone can reveal.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readCell MetabolismNov 3, 2026

ENDOCRINOLOGY · CLINICAL PRACTICE

Lipid organization in health and disease

In this Voices piece, our authors explore these themes through specific examples. Lipids are spatially and dynamically organized-within organelles, across cell types and organs, and in response to microbial and dietary inputs.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readCell MetabolismNov 3, 2026

CARDIOLOGY · RANDOMIZED CLINICAL TRIAL

Intensive vs More Intensive Lipid-Lowering Therapy and Plaque Regression in Statin-Naive Patients: Prespecified Analyses From the FLOWPROMOTE Randomized Clinical Trial

This secondary analysis of the FLOWPROMOTE randomized clinical trial demonstrated that in statin-naive patients with CAD, more intensive lipid-lowering therapy was associated with significantly greater regression of total and noncalcified coronary plaque burden compared with intensive therapy. The extent of plaque regression was related to achieved LDL-C levels, supporting the potential for partial reversal of coronary atherosclerosis with intensive lipid reduction.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readJAMA CardiologyOct 30, 2026

ENDOCRINOLOGY · PHASE III

Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial

In Japanese adults with obesity disease, once-daily orforglipron resulted in statistically superior reductions in bodyweight versus placebo (inactive comparison treatment), with a safety profile consistent with that of other GLP-1 receptor agonists. Orforglipron, a small-molecule, non-peptide, oral GLP-1 receptor agonist, has shown bodyweight reduction and cardiometabolic benefits in adults with obesity across Phase 3 trials globally.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readThe Lancet Diabetes & EndocrinologyOct 30, 2026

IMMUNOLOGY · REAL-WORLD COHORT

Spatial transcriptomics in immune-mediated necrotising myopathy uncovers a specific necrotic signature related to immune-driven fibrosis

In conclusion, IMNM necrotic muscle areas are linked to a specific SFRP4-expressing fibroblast subtype interacting with macrophages, potentially driving the pathological muscle phenotype and contributing to inflammation, fibro-fatty replacement, and strength loss. These cells carried a strong proportion of IMNM-enriched pathological signatures, notably a complement-linked 'tumour-like' inflammatory fibroblast signature and a specific interferon (an immune-signaling protein) response, characterised by the expression of metallothioneins.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readAnnals of the Rheumatic DiseasesOct 30, 2026

INFECTIOUS DISEASE · CLINICAL PRACTICE

Metabolic heterogeneity of obesity

A better understanding of the differences between metabolically divergent groups and the physiological responses to weight loss can help identify the factors responsible for the link between excess adiposity and metabolic dysfunction and disease. In this Review, we discuss metabolic differences at the cellular, organ-system and systemic levels between people with metabolically healthy and metabolically unhealthy obesity; we also discuss heterogeneity in the therapeutic effects of weight reduction.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readNature MedicineOct 27, 2026

GASTROENTEROLOGY · REAL-WORLD COHORT

Phase 1b study of miricorilant in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH)

Intermittent miricorilant dosing of 100 mg twice weekly achieved meaningful reductions in LFC and improved liver health markers with a favorable safety profile. Miricorilant, an oral nonsteroidal selective glucocorticoid receptor modulator, is being investigated as a therapy that modulates hepatic cortisol activity in patients with metabolic dysfunction-associated steatohepatitis (MASH).

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readHepatology (baltimore, Md.)Oct 26, 2026

Showing 12 of 20 medical briefings

Interactive Fact Check